Peter A. Lio, MD, provides an overview of the pathophysiology of atopic dermatitis (AD) and the comorbidities often associated with it.
Improving Quality of Life in Atopic Dermatitis With Targeted Therapies
Expert dermatologists review the impact of atopic dermatitis on quality of life for both the patient and their families.
Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.
Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.
Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.
Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.
Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.
Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.
Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.
Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.
Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.
Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.
Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.
Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.
Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
2
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
3
New Nonsteroidal Options Are Reshaping Pediatric Atopic Dermatitis Care
4
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
5